Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK's Fluarix Gets FDA Nod Under Accelerated Approval Process

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline expects to provide 8 mil. doses of its influenza vaccine for the 2005-2006 season.

You may also be interested in...



GSK’s Second Flu Vaccine Would Boost Capacity To 30 Mil. Doses

GSK submits a BLA for FluLaval, acquired as part of its 2005 purchase of ID Biomedical, to FDA March 23.

GSK’s Second Flu Vaccine Would Boost Capacity To 30 Mil. Doses

GSK submits a BLA for FluLaval, acquired as part of its 2005 purchase of ID Biomedical, to FDA March 23.

GSK To Gain Fluviral Vaccine Through Acquisition Of ID Biomedical

GlaxoSmithKline plans to acquire ID Biomedical for $1.4 bil., a deal that could provide GSK with a second flu vaccine in the U.S. for the 2006/2007 flu season.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS062820

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel